HCG vs Tamoxifen
FDA Approved vs FDA Approved
synergistic Researched · 95% HCG directly stimulates Leydig cells via LH receptor agonism while tamoxifen increases endogenous LH and FSH through hypothalamic estrogen receptor blockade. A common PCT protocol uses HCG first to prime the testes followed by tamoxifen to restore the HPTA axis.
Molecular Data
HCG Tamoxifen
Weight 36,700 Da 371.51 Da
Half-life 24-36 hours ~5-7 days
Chain 237 amino acids (alpha: 92, beta: 145) —
Type Heterodimeric glycoprotein Triphenylethylene-derived selective estrogen receptor modulator
Key Benefits
HCG
01 Maintains testicular function during TRT
02 Preserves fertility and prevents testicular atrophy
03 Stimulates endogenous testosterone production
04 Induces ovulation in women
05 FDA-approved for multiple indications
06 Well-established safety profile
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Dosing Protocols
HCG
250-1500 IU (lower for TRT adjunct, higher for fertility) / 2-3 times weekly, or every other day for lower doses
TRT Adjunct (Low) 250-500 IU Every other day
TRT Adjunct (Standard) 500-1000 IU Twice weekly
HCG Monotherapy 1500-2000 IU 2-3x weekly
Fertility (with FSH) 1500-2000 IU 2-3x weekly
Cryptorchidism (Pediatric) 1000-5000 IU 2-3x weekly for 3-4 weeks
Ovulation Trigger (Female) 5000-10,000 IU Single dose
PCT Protocol 1000-1500 IU Every other day for 2-3 weeks
Tamoxifen
20-40mg oral daily / Once daily
Side Effects
HCG
Gynecomastia (breast tenderness/swelling) due to increased estrogen
Headaches, irritability, and mood swings (especially initially)
Fluid retention and edema
Potential antibody formation with long-term use
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Contraindications
Hormone-sensitive cancers (prostate, breast)
Pregnancy (except as prescribed)
Precocious puberty risk in children
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Research Evidence
HCG Tamoxifen
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2024 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.